Expert Review of Neurotherapeutics最新文献_第4页

An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms. 图雷特综合征药物治疗和新兴治疗模式的最新进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-21 DOI: 10.1080/14737175.2024.2382463

Abhishek Lenka, Joseph Jankovic

{"title":"An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms.","authors":"Abhishek Lenka, Joseph Jankovic","doi":"10.1080/14737175.2024.2382463","DOIUrl":"10.1080/14737175.2024.2382463","url":null,"abstract":"Introduction: Tourette syndrome (TS) is a childhood-onset neurobehavioral disorder characterized by tics. Pharmacotherapy is advised for patients whose symptoms affect their quality of life.Areas covered: The authors review the tic phenomenology and TS diagnostic criteria. The bulk of this article focuses on pharmacotherapeutic options for treating tics. They also highlight pharmacotherapies in the research pipeline.Expert opinion: Tic treatment must be tailored to individual needs. Behavioral therapy is the first line of treatment. Most with bothersome tics need pharmacotherapy and rarely, for medication-refractory cases, surgical therapy is indicated. Alpha-2 agonists are considered in patients with mild tics, especially in those with attention deficit with or without hyperactivity. Second-generation antipsychotics like aripiprazole and tiapride may be considered for severe tics. However, prescribers should be mindful of potential side effects, especially drug-induced movement disorders. Botulinum toxin injections may be considered for focal motor tics. Topiramate can be considered when other treatments are ineffective, and its benefits outweigh the risks. The same holds true for vesicular monoamine transporter-2 inhibitors, as they are deemed to be safe and effective in real-world use and open-label trials despite not meeting primary endpoints in placebo-controlled trials. Cannabinoids may be considered in adults if the approaches above do not control tics.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1025-1033"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why is ADHD so difficult to diagnose in older adults? 为什么诊断老年人多动症如此困难？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-04 DOI: 10.1080/14737175.2024.2385932

David W Goodman, Samuele Cortese, Stephen V Faraone

引用次数: 0

The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature. 髓鞘少突胶质细胞糖蛋白-免疫球蛋白 G 相关疾病（MOGAD）的药物治疗：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-07 DOI: 10.1080/14737175.2024.2385941

Giuseppe Schirò, Salvatore Iacono, Giuseppe Salemi, Paolo Ragonese

{"title":"The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature.","authors":"Giuseppe Schirò, Salvatore Iacono, Giuseppe Salemi, Paolo Ragonese","doi":"10.1080/14737175.2024.2385941","DOIUrl":"10.1080/14737175.2024.2385941","url":null,"abstract":"Introduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD) is a clinical entity distinct from multiple sclerosis and aquaporin-4 (AQP4+)-IgG-positive neuromyelitis optica spectrum disorder. There is a lack of evidence regarding the efficacy and safety of current treatments used for MOGAD.Areas covered: In this article, the authors review the currently available literature on the pharmacological management of MOGAD. This article is based on an extensive search for articles including meta-analyses, clinical trials, systematic reviews, observational studies, case series and case reports.Expert opinion: Intravenous high-dose methylprednisolone is the most common therapy for acute attack with patients having a good treatment response. In cases with poor recovery, intravenous immunoglobulins (IVIG) or plasma-exchange proved to be effective. Maintenance therapies include mycophenolate mofetil, azathioprine, IVIG, oral corticosteroids, rituximab, and interleukin-6 receptor (IL6-R) antagonists. Rituximab is the most used drug while IL6-R antagonists emerged as an effective option for people not responding to current treatments. Larger prospective studies with longer follow-ups are needed to confirm whether the blockage of the IL6-R is an effective and safe option. Since there is no evidence of major safety issues related to the new available therapies, the authors believe that waiting for disease activity to consider a possible treatment change, is an unwise approach.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"985-996"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington's disease. 亨廷顿氏病患者激动和攻击行为的抗精神病药物选择指南。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-09 DOI: 10.1080/14737175.2024.2376836

James E Eaton, Daniel O Claassen

引用次数: 0

Advances in the management of bipolar disorder in children and adolescents: an update on the literature. 儿童和青少年躁郁症的治疗进展：最新文献。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-05 DOI: 10.1080/14737175.2024.2386429

Andrea Amerio, Gabriele Arduino, Fabio Fesce, Alessandra Costanza, Andrea Aguglia, Mario Amore, Gianluca Serafini

{"title":"Advances in the management of bipolar disorder in children and adolescents: an update on the literature.","authors":"Andrea Amerio, Gabriele Arduino, Fabio Fesce, Alessandra Costanza, Andrea Aguglia, Mario Amore, Gianluca Serafini","doi":"10.1080/14737175.2024.2386429","DOIUrl":"10.1080/14737175.2024.2386429","url":null,"abstract":"Introduction: Early diagnosis and treatment concerning bipolar disorder (BD) are related to a better functioning over the long-term period. Although pharmacotherapy is indicated for approximately all youths with BD, nearly one-third of patients do not receive adequate medications for their condition.Areas covered: The authors discuss the available scientific evidence from the current literature about the management of BD in both children and adolescents, giving particular focus to the efficacy and tolerability of the available pharmacological agents. Studies were identified searching MEDLINE and retrieved from reference listings of relevant articles and through consultation with experts in the field.Expert opinion: Many D2-blockers, approved by the Food and Drug Administration (FDA) based on their antimanic properties in youths, are related to both short- and long-term side effects. Lurasidone was found to be effective for the treatment of acute juvenile bipolar depression, while lithium for the treatment and recurrence prevention of manic/mixed episodes. The most common anticonvulsants were found to be most useful as adjunctive antimanic agents in non-responders to first-line monotherapies. No data was found to support the use of antidepressants in juvenile BD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1011-1024"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting and improving outcome in severe pediatric traumatic brain injury. 预测和改善严重小儿脑外伤的预后。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1080/14737175.2024.2389921

Mathilde Chevignard, Hugo Câmara-Costa, Georges Dellatolas

{"title":"Predicting and improving outcome in severe pediatric traumatic brain injury.","authors":"Mathilde Chevignard, Hugo Câmara-Costa, Georges Dellatolas","doi":"10.1080/14737175.2024.2389921","DOIUrl":"10.1080/14737175.2024.2389921","url":null,"abstract":"Introduction: Severe pediatric traumatic brain injury (spTBI), including abusive head trauma (AHT) in young children, is a major public health problem. Long-term consequences of spTBI include a large variety of physical, neurological, biological, cognitive, behavioral and social deficits and impairments.Areas covered: The present narrative review summarizes studies and reviews published from January 2019 to February 2024 on spTBI. Significant papers published before 2019 were also included. The article gives coverage to the causes of spTBI, its epidemiology and fatality rates; disparities, inequalities, and socioeconomic factors; critical care; outcomes; and interventions.Expert opinion: There are disparities between countries and according to socio-economic factors regarding causes, treatments and outcomes of spTBI. AHT has an overall poor outcome. Adherence to critical care guidelines is imperfect and the evidence-base of guidelines needs further investigations. Neuroimaging and biomarker predictors of outcomes is a rapidly evolving domain. Long-term cognitive, behavioral and psychosocial difficulties are the most prevalent and disabling. Their investigation should make a clear distinction between objective (clinical examination, cognitive tests, facts) and subjective measures (estimations using patient- and proxy-reported questionnaires), considering possible common source bias in reported difficulties. Family/caregiver-focused interventions, ecological approaches, and use of technology in delivery of interventions are recommended to improve long-term difficulties after spTBI.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"963-983"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability. 分析阿杜单抗作为阿尔茨海默病治疗方案的疗效、安全性和耐受性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-18 DOI: 10.1080/14737175.2024.2402058

Shreeya Thussu,Aniketh Naidu,Sindhu Manivannan,George T Grossberg

{"title":"Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability.","authors":"Shreeya Thussu,Aniketh Naidu,Sindhu Manivannan,George T Grossberg","doi":"10.1080/14737175.2024.2402058","DOIUrl":"https://doi.org/10.1080/14737175.2024.2402058","url":null,"abstract":"INTRODUCTIONAlzheimer's disease is the most common form of dementia worldwide. Aducanumab, a monoclonal antibody targeting amyloid-beta, became the first disease-modifying treatment for mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia and suggested that removing amyloid from the brain, especially in early AD, might make a difference in slowing cognitive decline.AREAS COVEREDIn this review, the authors outline aducanumab's clinical efficacy as shown through key clinical trials and discuss its approval by the Food and Drug Administration under the accelerated pathway, which sparked both hope and controversy. We also discuss the importance of amyloid-related imaging abnormalities as a major side effect of aducanumab and all subsequent monoclonal antibodies targeting amyloid-beta.EXPERT OPINIONAducanumab, became the first monoclonal antibody that provided at least partial support for the amyloid hypothesis by demonstrating slowed cognitive decline by removing amyloid from the brain, although full FDA approval now seems unlikely due to discontinuation of its development. Its introduction raised awareness of ARIA, highlighted the significant costs and need for informed consent in treatment, and emphasized the importance of long-term, diverse, and combination therapy data for future AD treatments targeting amyloid and tau.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"402 1","pages":"1-9"},"PeriodicalIF":4.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Rimegepant 和 atogepant：为偏头痛治疗提供创新机会的新型药物。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-12 DOI: 10.1080/14737175.2024.2401558

William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti

{"title":"Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.","authors":"William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti","doi":"10.1080/14737175.2024.2401558","DOIUrl":"https://doi.org/10.1080/14737175.2024.2401558","url":null,"abstract":"INTRODUCTIONRimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity and clinical flexibility attributed to the individual members of the gepant medication class.AREAS COVEREDThis review provides a brief review of the current uses, common adverse events, and potential areas of future clinical innovation attributed to rimegepant and atogepant. A database search for the term 'Rimegepant OR Atogepant' was completed, yielding 240 individual results. Following multiple rounds of assessment that aimed to determine relevance of each individual result, 42 studies were included in the synthesis of this review.EXPERT OPINIONRimegepant and atogepant are exciting medications that demonstrate significant clinical innovation within the field of migraine therapy. While current indications are clear, data is lacking regarding the future expanded roles of these medications. Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and breastfeeding, in cluster headache and post-traumatic headache, and in patients that previously discontinued calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"6 1","pages":"1-11"},"PeriodicalIF":4.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sacroiliac joint pain: what treatment and when. 骶髂关节疼痛：何时治疗？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-11 DOI: 10.1080/14737175.2024.2400682

Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini

{"title":"Sacroiliac joint pain: what treatment and when.","authors":"Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini","doi":"10.1080/14737175.2024.2400682","DOIUrl":"https://doi.org/10.1080/14737175.2024.2400682","url":null,"abstract":"INTRODUCTIONSpinal and non-spinal pathologies can cause low back pain. Non-spinal sources of low back pain include the sacroiliac joint (SIJ) and the hip. SIJ pain can be treated either conservatively or surgically. Current strategies for managing sacroiliac joint pain are debated, and limited evidence exists.AREAS COVEREDThe present expert opinion updates current evidence on conservative and surgical modalities for SIJ pain.EXPERT OPINIONSurgical management for SIJ pain is effective. However, it exposes patients to surgery and, therefore, related complications. Conservative management may be implemented in patients with moderate SIJ pain, with less than six months of symptoms, or not eligible for surgery. Several noninvasive modalities are available, mostly centered on intra-articular injections. Corticosteroids, platelet-rich plasma, and stem cells have only midterm lasting effects, at most for nine months. Radiofrequency ablation is another methodology for pain relief. Both continuous and pulsatile radiofrequency ablation are associated with good outcomes. SIJ fusion can be performed using different techniques; however, a clear recommendation on the most appropriate modality for the management of SIJ pain is still debated.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"15 1","pages":"1-8"},"PeriodicalIF":4.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When is pharmacological intervention recommended for adults with social anxiety disorder? 何时建议对患有社交焦虑症的成年人进行药物干预？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-10 DOI: 10.1080/14737175.2024.2401556

Franklin R Schneier

引用次数: 0